In a glioma model, C1142 treatment significantly reduced the total numbers of CD11b+CD45+ TAMs and CD11b+Gr1+ MDSCs, inhibiting tumour proliferation and prolonging the survival of glioma‐bearing mice.137. This evidence concerns the gene PTPRC and central nervous system cancer.